Abstract
To investigate the repression of miR-184 on Stanniocalcin-2 (STC2) and how this axis affects the propagation, invasiveness and migration ability of glioblastoma cells. RT-PCR was employed to determine the miR-184 and STC2 mRNA expression both in tissues and cells. Western blot was employed to determine the protein expression levels. The cells were transfected via lipofection. MTT, colony formation, invasion and scratch healing assays were conducted to study the propagation, invasiveness and migratory ability of glioblastoma cells, respectively. The dual luciferase reporter gene assay was conducted to determine whether miR-184 could directly bind to STC2 mRNA 3’UTR. MiR-184 was under-expressed whereas STC2 was over-expressed in glioblastoma tissues and cell line. The up-regulation of miR-184 significantly suppressed the propagation, migratory ability and invasion of glioblastoma cells, whereas the over-expression of STC2 restored this effect. MiR-184 was confirmed to directly target STC2. MiR-184 could retard the propagation, invasiveness and migratory ability of glioblastoma cells by suppressing STC2.
Similar content being viewed by others
Change history
25 April 2024
Following publication, concerns were raised on the PubPeer platform regarding the validity of the data in the article. An investigation by the Editorial Office, conducted in accordance with Pathology and Oncology Research policies, was unable to confirm the validity of the data presented and as such cannot confirm its reliability. The article is therefore retracted. This retraction was approved by the Editor-in-Chief of Pathology and Oncology Research. The authors received communication regarding the retraction but did not respond. The communication has been recorded by the publisher. Pathology and Oncology Research would like to thank the concerned reader who contacted us regarding the published article.
References
Kouhkan F, Mobarra N, Soufi-Zomorrod M et al (2016) MicroRNA-129-1 acts as tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1. J Med Genet 53:24–33
Zhen L, Li J, Zhang M, et al. MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT. J Biol Res (Thessalon). 2016;23:14
Zhang W, Zhang J, Yan W et al (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119:814–824
Sizoo EM, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology 12:1162–1166
Agnihotri S, Burrell KE, Wolf A et al (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp 61:25–41
Cheng Z, Wang HZ, Li X et al (2015) MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma. J Exp Clin Cancer Res 34:27
Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159
Sethi S, Ali S, Sethi S et al (2014) MicroRNAs in personalized cancer therapy. Clin Genet 86:68–73
Yang BF, Lu YJ, Wang ZG (2009) MicroRNAs and apoptosis: implications in the molecular therapy of human disease. Clin Exp Pharmacol Physiol 36:951–960
Zhou R, Zhou X, Yin Z et al (2015) Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer. Oncotarget 6:44609–44622
Su Z, Chen D, Li Y et al (2015) microRNA-184 functions as tumor suppressor in renal cell carcinoma. Exp Ther Med 9:961–966
Qin CZ, Lou XY, Lv QL et al (2015) MicroRNA-184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation. Pharmazie 70:668–673
Feng R, Dong L (2015) Inhibitory effect of miR-184 on the potential of proliferation and invasion in human glioma and breast cancer cells in vitro. Int J Clin Exp Pathol 8:9376–9382
Malzkorn B, Wolter M, Liesenberg F et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20:539–550
Chang AC, Janosi J, Hulsbeek M et al (1995) A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 112:241–247
Chang AC, Jeffrey KJ, Tokutake Y et al (1998) Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics 47:393–398
Wagner GF, Dimattia GE (2006) The stanniocalcin family of proteins. J Exp Zool A Comp Exp Biol 305:769–780
Ito D, Walker JR, Thompson CS et al (2004) Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 24:9456–9469
Gagliardi AD, Kuo EY, Raulic S et al (2005) Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs. Am J Physiol Endocrinol Metab 288:E92–105
Wang Y, Gao Y, Cheng H et al (2015) Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer. Biochem Biophys Res Commun 466:362–368
Na SS, Aldonza MB, Sung HJ et al (1854) Stanniocalcin-2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression. Biochim Biophys Acta 2015:668–676
Hou J, Wang Z, Xu H et al (2015) Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling. PLoS One 10:e0122179
Guo GX, Li QY, Ma WL et al (2015) MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin Exp Pathol 8:12292–12299
Lin S, Guo Q, Wen J et al (2014) Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res 33:26
Su J, Guo B, Zhang T et al (2015) Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients. Tumour Biol 36:6333–6339
Yamamoto K, Tajima Y, Hasegawa A et al (2016) Contrasting effects of stanniocalcin-related polypeptides on macrophage foam cell formation and vascular smooth muscle cell migration. Peptides 82:120–127
Jepsen MR, Kloverpris S, Botkjaer JA et al (2016) The proteolytic activity of pregnancy-associated plasma protein-a is potentially regulated by stanniocalcin-1 and -2 during human ovarian follicle development. Hum Reprod 31:866–874
Zhou H, Li YY, Zhang WQ et al (2014) Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters. PLoS One 9:e95466
Law AY, Wong CK (2013) Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways. Mol Cell Endocrinol 374:73–81
Yao YL, Ma J, Wang P et al (2015) miR-101 acts as a tumor suppressor by targeting Kruppel-like factor 6 in glioblastoma stem cells. CNS Neurosci Ther 21:40–51
Yuan Q, Gao W, Liu B et al (2014) Upregulation of miR-184 enhances the malignant biological behavior of human glioma cell line A172 by targeting FIH-1. Cell Physiol Biochem 34:1125–1136
Gao B, Gao K, Li L et al (2014) miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomed Pharmacother 68:143–148
Zhen Y, Liu Z, Yang H et al (2013) Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis 4:e872
Wagner GF, Jaworski E (1994) Calcium regulates stanniocalcin mRNA levels in primary cultured rainbow trout corpuscles of stannius. Mol Cell Endocrinol 99:315–322
Shen XJ, Gu K, Shi JP et al (2014) Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma. Int J Clin Exp Pathol 7:8770–8776
Arigami T, Uenosono Y, Ishigami S et al (2013) Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer. Oncol Rep 30:2838–2844
Wang H, Wu K, Sun Y et al (2012) STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep 45:629–634
Funding
No funding was received.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The research has been carried out in accordance with the World Medical Association Declaration of Helsinki.
Conflict of Interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Feng, L., Ma, J., Ji, H. et al. RETRACTED ARTICLE: MiR-184 Retarded the Proliferation, Invasiveness and Migration of Glioblastoma Cells by Repressing Stanniocalcin-2. Pathol. Oncol. Res. 24, 853–860 (2018). https://doi.org/10.1007/s12253-017-0298-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-017-0298-z